Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: WELL stock price vs EQIX: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at EQIX's multiple
Needs EQIX P/E.
Implied fair value · at WELL's multiple
Needs WELL P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Eight period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
WELLTOWER INC. · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
EQUINIX INC · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Ventas, Inc.
WELL vs VTR
OMEGA HEALTHCARE INVESTORS INC
WELL vs OHI
COSTAR GROUP, INC.
WELL vs CSGP
Prologis, Inc.
WELL vs PLD
Public Storage
WELL vs PSA
EQUITY RESIDENTIAL
WELL vs EQR
DIGITAL REALTY TRUST, INC.
WELL vs DLR
AMERICAN TOWER CORP /MA/
WELL vs AMT
CROWN CASTLE INC.
WELL vs CCI
IRON MOUNTAIN INC
WELL vs IRM
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe WELL can sustain 35.6% revenue growth while rapidly expanding margins and reducing 9.2x net debt/EBITDA, then hold or accumulate; otherwise, the current valuation looks hard to justify versus EQIX and EQIX-implied downside is substantial.
WELL trades at a steep premium to EQIX-derived valuation reference, with an implied price of $107.06 versus a current price of $206.77, or -48.2% downside. The gap is not just a P/E story: WELL also looks expensive on EV/EBITDA and EV/Revenue while its historical band suggests the stock is already near the upper end of its own range.
Supporting Metrics
